Stevanato Group SpA

Stevanato Group SpA(STVN)股票分析

$18.900

-0.344 (-1.82%)收盤時

Loading chart…
最高
19.270
開盤
19.270
成交量加權均價
18.89
成交量
277.78K
市值
5.11B
最低
18.510
成交金額
5.25M
企業價值/稅息折舊攤銷前利潤(TTM)
16.85

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

AI 分析 of Stevanato Group SpA (STVN)

持有

Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.

估值指標

Stevanato Group SpA(STVN)目前預期本益比為 29.15,5 年平均預期本益比為 35.47。

預期本益比

合理
5 年均值 P/E
35.47
目前P/E
29.15
高估
44.83
低估
26.12

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
19.14
目前EV/EBITDA
16.85
高估
23.18
低估
15.10

預期股價營收比

合理
5 年均值 P/S
4.81
目前P/S
3.80
高估
5.87
低估
3.74

Alphio AI 對 STVN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%STVN

$30.64

情境價格

基

基準

基準 · 50%STVN

$26.84

情境價格

悲

悲觀

悲觀 · 25%STVN

$25.76

情境價格

持有 STVN 的大戶

V

Van Berkom and Associates Inc.

+ 持有STVN

+0.24%

3個月報酬率

S

Stevanato Holding S.R.L.

+ 持有STVN

-1.31%

3個月報酬率

事件時間軸

2026-08-04 (ET)

07:00:00

Stevanato Reports Q2 Revenue of €302.0M

07:00:00

Company Narrows 2026 Revenue View to EUR1.26B-EUR1.28B

2026-07-30 (ET)

08:00:00

Stevanato Group Receives Marketing Authorization for Alina Injector in Europe

2025-12-01 (ET)

16:40:00

Morgan Stanley Rates Stevanato Group Equal Weight with $24 Price Target, Downgraded from $26

2025-11-06 (ET)

06:59:13

Stevanato Group projects adjusted EPS of EUR0.50-EUR0.54 for 2025

資訊

STVN 常見問題 —— 由 Alphio AI 解答

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易